New pharmacological approaches in heart failure therapy: developments and possibilities.
There have been few major breakthroughs in heart failure (HF) drug therapies in recent years yet HF morbidity and mortality remain high, and there is a clear need for further research. Several newer agents that appear promising in Phase I and II trials do not progress to show clinical benefit in later trials. Part of the failure to find new therapies may lie in flawed trial design compounded by the need for ever-increasing patient numbers in order to prove outcome benefit. We summarize some of the most recent and promising medical therapies for HF.
Department of Cardiology, Hull York Medical School, Hull & East Yorkshire Medical Research & Teaching Centre, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK.
Joseph J
JJ
Cuthbert
Department of Cardiology, Hull York Medical School, Hull & East Yorkshire Medical Research & Teaching Centre, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK.
Pierpaolo
P
Pellicori
Department of Cardiology, Hull York Medical School, Hull & East Yorkshire Medical Research & Teaching Centre, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK.
Parin
P
Shah
Department of Cardiology, Hull York Medical School, Hull & East Yorkshire Medical Research & Teaching Centre, Castle Hill Hospital, Cottingham, Kingston upon Hull HU16 5JQ, UK.
Andrew L
AL
Clark
D000577:Amides / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004232:Diuretics / Q000627:therapeutic use; D005544:Forecasting; D005650:Fumarates / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006947:Hyperkalemia / Q000188:drug therapy; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009200:Myocardial Contraction / Q000187:drug effects; D009287:Naphthyridines / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use
D000577:Amides; D002316:Cardiotonic Agents; D004232:Diuretics; D005650:Fumarates; D000451:Mineralocorticoid Receptor Antagonists; D009287:Naphthyridines; D009842:Oligopeptides; D014665:Vasodilator Agents; C576501:finerenone; C446481:aliskiren; C555534:Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH
HeFNEF; HeFREF; heart failure; new therapies; new treatments